CERo Therapeutics Holdings - CERO Net earnings per share for the last 12 months

CERo Therapeutics (CERO) - corporate logo

By adhering to ethical testing standards and environmental waste disposal, CERo Therapeutics minimizes risks. The GURU.Markets portal provides this chart, where the annual net income per share TTM dynamics illustrate the current trend, and the value captures this metric. The company's revenues are based on innovations in cell therapy, while an intensive R&D pipeline featuring T-Chime technology ensures a technological breakthrough.

cero.bio (CERO): Earnings per share for the last twelve months from 07/04/2022 to 11/18/2026

Financial and market metric breakdowns for CERo Therapeutics Holdings (CERO)

Fundamental company valuation:CERO CERo Therapeutics Holdings, Inc.
Flagship merchandise of cero.bio

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period. Investors analyze current EPS YoY TTM momentum to identify hidden fundamental trends between quarterly reports. This metric reflects the efficiency of profit capitalization. For CERo Therapeutics (CERO), this indicator is secondary, as biotech success depends on clinical trials rather than economic cycles. Profit dynamics here only indirectly indicate the cost of attracting R&D financing.